Asset Management One Co. Ltd. Raises Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Asset Management One Co. Ltd. raised its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 4.7% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 68,457 shares of the biopharmaceutical company's stock after purchasing an additional 3,094 shares during the quarter. Asset Management One Co. Ltd. owned approximately 0.05% of Alnylam Pharmaceuticals worth $18,485,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Larson Financial Group LLC lifted its holdings in shares of Alnylam Pharmaceuticals by 187.2% during the fourth quarter. Larson Financial Group LLC now owns 112 shares of the biopharmaceutical company's stock worth $26,000 after buying an additional 73 shares in the last quarter. Park Square Financial Group LLC bought a new position in shares of Alnylam Pharmaceuticals in the fourth quarter worth $28,000. Whipplewood Advisors LLC increased its position in shares of Alnylam Pharmaceuticals by 208.8% in the first quarter. Whipplewood Advisors LLC now owns 105 shares of the biopharmaceutical company's stock worth $28,000 after purchasing an additional 71 shares during the period. OFI Invest Asset Management bought a new position in Alnylam Pharmaceuticals in the fourth quarter valued at about $35,000. Finally, Colonial Trust Co SC bought a new position in Alnylam Pharmaceuticals in the fourth quarter valued at about $35,000. Institutional investors and hedge funds own 92.97% of the company's stock.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on the company. Needham & Company LLC lifted their target price on Alnylam Pharmaceuticals from $320.00 to $377.00 and gave the company a "buy" rating in a research report on Thursday. Royal Bank Of Canada boosted their price objective on Alnylam Pharmaceuticals from $310.00 to $330.00 and gave the stock an "outperform" rating in a report on Friday, March 21st. Wells Fargo & Company lifted their target price on Alnylam Pharmaceuticals from $275.00 to $287.00 and gave the company an "equal weight" rating in a research report on Friday, March 21st. HC Wainwright reiterated a "buy" rating and set a $500.00 price target on shares of Alnylam Pharmaceuticals in a report on Wednesday, April 2nd. Finally, Bank of America upped their price objective on Alnylam Pharmaceuticals from $302.00 to $325.00 and gave the company a "buy" rating in a research note on Friday, March 21st. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and twenty have given a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $337.91.

Alnylam Pharmaceuticals Price Performance

Shares of Alnylam Pharmaceuticals stock traded up $4.58 during trading on Friday, hitting $322.83. 2,051,645 shares of the stock traded hands, compared to its average volume of 868,728. The company has a quick ratio of 2.98, a current ratio of 3.04 and a debt-to-equity ratio of 8.88. The stock has a market cap of $42.09 billion, a price-to-earnings ratio of -154.46 and a beta of 0.22. The firm's fifty day moving average is $286.24 and its 200-day moving average is $263.26. Alnylam Pharmaceuticals, Inc. has a 52 week low of $205.87 and a 52 week high of $326.03.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last announced its quarterly earnings data on Thursday, May 1st. The biopharmaceutical company reported ($0.44) EPS for the quarter, missing the consensus estimate of ($0.37) by ($0.07). The firm had revenue of $594.19 million for the quarter, compared to the consensus estimate of $584.32 million. Alnylam Pharmaceuticals had a negative net margin of 11.49% and a negative return on equity of 510.31%. Alnylam Pharmaceuticals's revenue for the quarter was up 20.2% compared to the same quarter last year. During the same quarter last year, the company posted ($0.16) earnings per share. Research analysts expect that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current fiscal year.

Insider Transactions at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, CEO Yvonne Greenstreet sold 19,297 shares of Alnylam Pharmaceuticals stock in a transaction on Monday, June 2nd. The stock was sold at an average price of $306.00, for a total transaction of $5,904,882.00. Following the completion of the transaction, the chief executive officer now owns 48,948 shares in the company, valued at approximately $14,978,088. The trade was a 28.28% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 1.50% of the company's stock.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.